http://www.theravance.com/ http://finance.yahoo.com/q/ks?s=THRX http://www.form4oracle.com/company?cik=0001080014&ticker=thrx
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines in the United States. It develops medicines for respiratory diseases, bacterial infections, and gastrointestinal motility dysfunction. The company's development programs include Telavancin (cSSSI), a bactericidal injectable antibiotic, which is in NDA submission stage for the treatment of complicated skin and skin structure infections; Telavancin (HAP), which is in phase 3 clinical studies for hospital-acquired pneumonia; and Heterodimer, which is in phase 2 clinical studies for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, including MRSA. It also develops various long-acting beta2 agonist (LABA) product candidates for the treatment of asthma and chronic obstructive pulmonary diseases. The company's development programs also include GSK961081, a bifunctional muscarinic antagonist-beta2 agonist compound; TD-5742, a long-acting muscarinic antagonist compound; and TD-5108, an investigational selective 5-HT4 agonist, which is in phase 2 clinical studies for the treatment of chronic constipation and other disorders related to reduced gastrointestinal motility. Theravance has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin; GlaxoSmithKline plc to develop and commercialize LABA product candidates; and AstraZeneca AB to develop and commercialize intravenous anesthetic compound. The company also has a strategic alliance with GlaxoSmithKline plc. Theravance was founded in 1996. It was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in 2002. The company is headquartered in South San Francisco, California.